News &amp; Updates

Oral iron supplementation for 8 weeks results in significant improvements in postural control in young women with iron-deficiency anaemia (IDA).

Drospirenone safer than levonorgestrel when co-administered with psychotropics

For women using contraceptives while on psychotropic drugs, the risk of adverse events appears to be lower with drospirenone than with levonorgestrel, whereas contraceptive failure is uncommon across progestins, according to a real-world study.

NIPS regimen improves OS in gastric cancer with peritoneal metastasis

12 Mar 2025 by

Among patients with gastric cancer and peritoneal metastasis, treatment with neoadjuvant intraperitoneal–systemic (NIPS) regimen, which consists of intraperitoneal (IP) and intravenous (IV) paclitaxel plus S-1, significantly improved overall survival (OS) compared with IV paclitaxel plus S-1 only (PS regimen), according to the DRAGON-01 trial presented at ASCO GI 2025.

HPV vaccines useful for managing actinic keratosis

Standard α-HPV vaccination appears to reduce the burden of actinic keratosis (AK) in individuals with multiple lesions, according to the VAXAK trial.

Xanomeline/trospium improves cognition in acute schizophrenia patients with impairment

The use of xanomeline/trospium chloride brings significant cognitive improvements to acute schizophrenia patients with prespecified impairments compared with placebo, a study has shown.

Ondansetron plus SRI eases OCD severity

Treatment with high-dose ondansetron shows no effect on sensory phenomena (SP) in patients with obsessive-compulsive disorder (OCD), according to a study.

Radiotherapy plus short-course ADT confers survival benefit in oligometastatic prostate cancer

In patients with oligometastatic hormone-sensitive prostate cancer, the combination of stereotactic body radiotherapy (SBRT) plus a short course of androgen deprivation therapy (ADT) appears to improve progression-free survival (PFS), according to the phase II RADIOSA trial.

Japanese adults with obesity lose weight with once-weekly tirzepatide

Taking tirzepatide once a week appears to result in clinically meaningful reductions in body weight for Japanese adults with obesity, according to the results of the phase III multicentre SURMOUNT-J trial

Allergy history, previous exposure predict oxaliplatin hypersensitivity reactions

A history of allergy, previous oxaliplatin exposure, and chemotherapy regimens are associated with a higher risk of oxaliplatin hypersensitivity reactions in patients with colorectal cancer, reveals a study.

Original New Drug Application Approvals by US FDA (1-15 February 2025)

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.